Viyash expects BioForLife benefits in two to three years
Key highlights
- Viyash expects BioForLife cross-selling benefits to begin two to three years after the October 1, 2026 acquisition.
- Management said registrations take 15-18 months and marketing build-out adds six to eight months.
- Viyash has started geographic extension work on 10 BioForLife products in three therapy areas.
- Viyash targets Q1 FY28 commissioning for its companion-animal manufacturing facility.
powered by IRIS

Viyash Scientific Limited expects BioForLife cross-selling benefits to begin within two to three years of the October 1, 2026 acquisition, because registrations in new markets take 15-18 months and marketing build-out requires a further six to eight months. The acquired business will be consolidated from Q3 FY27.
Know Viyash Scientific inside out
Results, valuation, peers and who's buying, in one view.
When will Viyash see BioForLife cross-selling benefits?
Viyash expects BioForLife cross-selling benefits to start flowing in two to three years, rather than immediately after the October 1, 2026 consolidation date. Management linked the timetable to product registration and commercial-launch work needed to take established products into additional countries.
Viyash completed the acquisition of 100% of BioForLife Italia on October 1, 2026, making the Italian company a step-down wholly owned subsidiary. Its results were not part of H1 FY27, which ended September 30, 2026, and will instead be consolidated from Q3 FY27.
The intended benefit runs in two directions. Viyash plans to extend BioForLife products into countries where it has an existing commercial presence, while seeking to introduce Alivira products into Italy. Management said the timetable applies to both BioForLife product expansion and the launch of Alivira products in the Italian market.
Why does Viyash expect a two-to-three-year integration timeline?
Viyash expects the process to take two to three years because registration of a product in a new market takes 15-18 months, even when that product already exists elsewhere. Management said building marketing after registration takes another six to eight months before commercial benefits can begin to emerge.
The company has started geographical extension work on an initial list of 10 products in gastroenterology, dermatology and ophthalmology. The potential markets named by management include parts of Europe, Brazil, Latin America, Turkey and India, where Viyash already has frontend operations.
Existing commercial access does not remove regulatory requirements. Management specifically said that a new product or an expansion into a new market still needs registration, and the subsequent marketing effort is needed to establish sales. That sequence is why the October 2026 acquisition does not translate into a stated near-term cross-selling contribution.
What has Viyash started under the BioForLife integration plan?
Viyash has begun work on the 10-product BioForLife geographic-extension programme and is using the acquisition as a platform for companion-animal launches. The first product list covers gastroenterology, dermatology and ophthalmology, with work beginning after the October 1, 2026 acquisition close.
Viyash has also completed registration of its entity in Vietnam and started product registrations there. Management expects commercial sales in Vietnam to begin early in the next year, illustrating the registration-led market-entry process it described for its broader international expansion.
Brazil and Turkey are a separate focus because management believes local presence can shorten launch timing. Viyash is identifying strategic partners in both countries for technology transfer and local support, and management said such arrangements could accelerate selected launches by nine to 12 months.
The broader companion-animal pipeline includes multiple products with patent expiries through 2035. Viyash identified Europe, Brazil, Turkey, Mexico, India and Southeast Asia as initial target markets, and management said it could consider extending into other markets after gaining progress over roughly 24 months in the initial territories.
Got a follow-up? Ask IRIS
Is Viyash building capacity for the planned 2029 launches?
Viyash is increasing research, manufacturing and local-market capabilities for companion-animal launches planned from 2029. Management said animal-health research and development spending has risen threefold from the prior year to a run rate of almost Rs 10 crore per quarter, or at least Rs 40 crore annualised.
The animal-health research and development team has doubled, and the number of products moving annually to validation has increased from one or two before the merger to five to eight. Management said most products are proceeding to filing, while critical active pharmaceutical ingredient products are in validation or filing stages.
A dedicated companion-animal manufacturing facility is under construction and is targeted for commissioning in Q1 FY28. Viyash said this schedule should provide enough time for FY29 launch requirements, while existing capacity has been optimised and expanded by 20%-25% for the next one to two years.
Management also plans one more animal-health manufacturing line for the larger 2029 and 2030 opportunity. It said the line is expected to be started and completed in FY28, alongside efforts to build frontend teams internally and assess inorganic opportunities that could add commercial reach.
How does BioForLife fit Viyash's current financial position?
BioForLife joins Viyash after H1 FY27 revenue of Rs 1,934 crore, up 17.8% year on year, and pre-employee stock option plan earnings before interest, tax, depreciation and amortisation of Rs 412 crore, up 30%. The acquisition was completed after the September 30, 2026 half-year reporting date.
Profit after tax for H1 FY27 rose 49.4% to Rs 164 crore from Rs 110 crore in H1 FY26. Pre-employee stock option plan earnings before interest, tax, depreciation and amortisation margin increased to 21.3% from 19.3%, while gross margin was broadly unchanged at 53.9% versus 53.8%.
For Q2 FY27, revenue was Rs 988 crore, up 16.2% year on year, while pre-employee stock option plan earnings before interest, tax, depreciation and amortisation rose 10.3% to Rs 208 crore. The quarterly margin was 21.1%, compared with 22.1% in Q2 FY26, in contrast with the margin expansion reported for H1.
Net debt fell to Rs 26 crore on September 30, 2026, from Rs 166 crore in March 2026. Management said net debt to last-12-month earnings before interest, tax, depreciation and amortisation was close to zero, and attributed the H1 reduction in finance costs to debt reduction and balance-sheet strengthening.
Conclusion
The BioForLife acquisition gives Viyash an Italian platform, products and a route to cross-sell in markets where it already operates, but management does not expect meaningful benefits at once. The stated two-to-three-year period reflects a 15-18-month registration process and a further six to eight months of commercial preparation, beginning from the October 1, 2026 close.
The next disclosed milestones are the Q1 FY28 commissioning target for the dedicated companion-animal facility, the planned start and completion of another manufacturing line in FY28, and Vietnam commercial sales expected early in the next year. Management has also identified companion-animal launches from 2029 and says local partnerships in Brazil and Turkey could shorten selected launch schedules by nine to 12 months.


